Why collaborate with N-Power Medicine
N-Power Medicine is focused on bringing new cancer therapies to patients faster by collaborating with organizations across healthcare. Expanding access to clinical trials in the community setting could broaden access to innovative therapies. Today there are many challenges in conducting clinical trials in the community that we hope to address collaboratively. We are open to partnering with anyone committed to these same objectives.
COLLABORATION OPPORTUNITIES:
Advocacy Groups
We understand that amplifying the voice of the patient is essential to expand access and improve the conduct of clinical trials. N-Power Medicine is engaging patient groups at each stage of its development and are always interested in partnering with new groups that are committed to this same mission.
Biopharma Companies
Many companies are challenged to bring new novel therapies to patients quickly due challenges with patient recruitment. For those interested in accelerating clinical development programs, N-Power Medicine should be your partner of choice to access community sites that are ready to recruit patient populations that have been historically under-represented in clinical research.
Diagnostic Companies
Many companies are challenged to bring new novel diagnostics to patients quickly due to challenges with establishing clinical utility. For those innovative companies interested in accelerating clinical development programs, N-Power Medicine should be your partner of choice.
Digital Health Companies
Digital solutions will play an integral role in advancing healthcare, and N-Power Medicine plans to integrate the latest innovations at each stage of its development and looks to collaborate with the most innovative companies.
Oncology Centers
Many oncology practices aspire to expand clinical research programs that are seamlessly integrated with routine practice. Partnering with N-Power Medicine provides access to resources, staff, and an innovative portfolio of clinical trials to achieve this aspiration.